Immuno-STAT Autoimmune Program
Autoimmune Disease (undisclosed)
PreclinicalActive (Partnered with Boehringer Ingelheim)
Key Facts
Indication
Autoimmune Disease (undisclosed)
Phase
Preclinical
Status
Active (Partnered with Boehringer Ingelheim)
Company
About Cue Biopharma
Cue Biopharma is pioneering precision immunotherapies through its proprietary Immuno-STAT™ (Selective Targeting and Alteration of T Cells) platform. The company engineers biologics that mimic natural immune signals to selectively activate or suppress specific T cell populations, offering a targeted approach for autoimmune diseases and cancer. With a leadership team boasting deep experience from Novartis, Johnson & Johnson, and other industry leaders, Cue has secured strategic partnerships with Boehringer Ingelheim and ImmunoScape to advance its pipeline and technology.
View full company profile